Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Nephrology 2, 295 (1 June 2006) | doi:10.1038/ncpneph0186
Reversing the progression of polycystic kidney disease with an mTOR inhibitor
Abstract
Shillingford JM et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466–5471 Research published in the Proceedings of the National Academy of Sciences indicates that rapamycin—a drug already used as an immunosuppressant in renal transplantation—might be a potential treatment for the 12 million autosomal dominant polycystic kidney disease (ADPKD) sufferers worldwide.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
